PCI Biotech Holding — AGM Information 2016

Dec 8, 2016

PCI Biotech: Rights issue approved by the extraordinary general meeting

PCI Biotech: Rights issue approved by the extraordinary general meeting

Oslo 8 December, 2016. An extraordinary general meeting (the "EGM") of the

shareholders of PCI Biotech Holding ASA ("PCI Biotech") was held today, 8

December 2016 at 09:00 CET. 8,527,123 shares were represented at the meeting,

corresponding to 57.2 percent of the share capital.

The EGM approved the Board of Directors' proposed resolutions as set forth in

the notice of the EGM issued on 17 November 2016. Compared to the notice of the

extraordinary general meeting, the Board of Directors proposed at the general

meeting to revise the payment date in the rights issue from 12 to 16 January

2017, which amended proposal was resolved by the general meeting.

The PCI Biotech share will, for trades subject to the ordinary T+2 settlement in

the Norwegian Central Securities Depository (VPS), consequently trade exclusive

of the right to receive subscription rights in the rights issue from and

including tomorrow, 9 December 2016. Detailed terms of the rights issue will be

included in the prospectus, expected to be published on or about 14 December

The minutes of the EGM are attached, and are also available on

www.pcibiotech.com.

In PCI Biotech's stock exchange announcement dated 17 November 2016, the Company

communicated certain expected dates relative to the completion of the guaranteed

rights issue, of which some dates, upon further assessment, must be extended in

time. Given the current timetable, as will be communicated by the Company in

detail in the prospectus, the Company expects that the allocation date, whereby

allocations in the rights issue will be made and notified to the subscribers,

will be on or about 10 January 2017, payment date for the subscription amounts

will be on 16 January 2017 (as referenced above) and the registration of the

share capital increase in the Norwegian Register of Business Enterprises will be

completed on or about 20 January 2017.

Contact information:

Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757

For more information visit: www.pcibiotech.com

Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379

Oslo

Important Notice

The contents of this announcement have been prepared by, and are the sole

responsibility of, the Company. The Company's financial advisors are acting

exclusively  for  the  Company  and  no  one  else, and will not be responsible

to  anyone  other  than  the  Company for providing the protections afforded  to

their respective clients, or for advice in  relation to the Rights Issue, the

contents  of this  announcement or  any of  the matters  referred to herein. The

Rights Issue and the distribution of this announcement and other information in

connection with the Rights Issue may be restricted by law in certain

jurisdictions. The Company assumes no responsibility in the event there is a

violation by any person of such restrictions. Persons into whose possession this

announcement or such other information should come are required to inform

themselves about, and to observe, any such restrictions.

The Rights Issue will not be made in any jurisdiction or in any circumstances in

which such offer or solicitation would be unlawful. This announcement is not for

distribution, directly or indirectly in or into any jurisdiction in which it is

unlawful to make any such offer or solicitation to such person or where prior

registration or approval is required for that purpose. No steps have been taken

or will be taken relating to the Rights Issue in any jurisdiction outside of

Norway in which such steps would be required. Neither the publication and/or

delivery of this announcement shall under any circumstances imply that there has

been no change in the affairs of the Company or that the information contained

herein is correct as of any date subsequent to the earlier of the date hereof

and any earlier specified date with respect to such information.

This publication is not for distribution, directly or indirectly, in or into the

United States, nor is it an offer for sale of or the solicitation of an offer to

purchase securities in the United States. Any securities referred to herein have

not been registered under the U.S. Securities Act of 1933, as amended (the "U.S.

Securities Act"), and may not be offered or sold in the United States absent

registration or pursuant to an exemption from registration under the U.S.

Securities Act. Copies of this publication are not being, and may not be,

distributed or sent into the United States.

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.